351 related articles for article (PubMed ID: 21966212)
1. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.
Dickens JA; Lomas DA
Drug Des Devel Ther; 2011; 5():391-405. PubMed ID: 21966212
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
Franciosi AN; McCarthy C; McElvaney NG
Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
[TBL] [Abstract][Full Text] [Related]
3. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
Abboud RT; Ford GT; Chapman KR
Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
5. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of alpha-1-antitrypsin deficiency.
Duvoix A; Roussel BD; Lomas DA
Rev Mal Respir; 2014 Dec; 31(10):992-1002. PubMed ID: 25442121
[TBL] [Abstract][Full Text] [Related]
7. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights.
Gooptu B; Ekeowa UI; Lomas DA
Eur Respir J; 2009 Aug; 34(2):475-88. PubMed ID: 19648523
[TBL] [Abstract][Full Text] [Related]
9. Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency.
Lomas DA
COPD; 2013 Mar; 10 Suppl 1():17-25. PubMed ID: 23527623
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for alpha-1-antitrypsin deficiency.
Stockley RA
Expert Opin Emerg Drugs; 2010 Dec; 15(4):685-94. PubMed ID: 20716026
[TBL] [Abstract][Full Text] [Related]
11. Heteropolymerization of α-1-antitrypsin mutants in cell models mimicking heterozygosity.
Laffranchi M; Berardelli R; Ronzoni R; Lomas DA; Fra A
Hum Mol Genet; 2018 May; 27(10):1785-1793. PubMed ID: 29538751
[TBL] [Abstract][Full Text] [Related]
12. Alpha 1-antitrypsin deficiency and the impact of nursing interventions and treatment with intravenous therapy. An overview.
Scharnweber K
J Intraven Nurs; 1999; 22(5):258-64. PubMed ID: 10776189
[TBL] [Abstract][Full Text] [Related]
13. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
14. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
15. Alpha1-antitrypsin deficiency.
Stoller JK; Aboussouan LS
Lancet; 2005 Jun 25-Jul 1; 365(9478):2225-36. PubMed ID: 15978931
[TBL] [Abstract][Full Text] [Related]
16. Augmentation therapy in alpha-1 antitrypsin deficiency.
Heresi GA; Stoller JK
Expert Opin Biol Ther; 2008 Apr; 8(4):515-26. PubMed ID: 18352854
[TBL] [Abstract][Full Text] [Related]
17. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
18. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo.
Mahadeva R; Atkinson C; Li Z; Stewart S; Janciauskiene S; Kelley DG; Parmar J; Pitman R; Shapiro SD; Lomas DA
Am J Pathol; 2005 Feb; 166(2):377-86. PubMed ID: 15681822
[TBL] [Abstract][Full Text] [Related]
19. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
20. The role of bronchial epithelial cells in the pathogenesis of COPD in Z-alpha-1 antitrypsin deficiency.
Pini L; Tiberio L; Venkatesan N; Bezzi M; Corda L; Luisetti M; Ferrarotti I; Malerba M; Lomas DA; Janciauskiene S; Vizzardi E; Modina D; Schiaffonati L; Tantucci C
Respir Res; 2014 Sep; 15(1):112. PubMed ID: 25218041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
